within Pharmacolibrary.Drugs.ATC.S;

model S01BC10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.38 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 8.999999999999999e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) used as an ophthalmic solution to treat pain and inflammation associated with cataract surgery. It is a prodrug rapidly converted to amfenac in ocular tissues and is approved for topical ophthalmic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult human eyes after single or multiple topical ophthalmic administrations (0.1% nepafenac solution, typical clinical dose). The presented data pertain to the conversion to amfenac (active metabolite) in the aqueous humor.</p><h4>References</h4><ol><li><p>Jones, BM, &amp; Neville, MW (2013). Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. <i>The Annals of pharmacotherapy</i> 47(6) 892–896. DOI:<a href=&quot;https://doi.org/10.1345/aph.1R757&quot;>10.1345/aph.1R757</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23715071/&quot;>https://pubmed.ncbi.nlm.nih.gov/23715071</a></p></li><li><p>Sheppard, JD, et al., &amp; Jasek, MC (2018). In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. <i>Ophthalmology and therapy</i> 7(1) 157–165. DOI:<a href=&quot;https://doi.org/10.1007/s40123-018-0130-1&quot;>10.1007/s40123-018-0130-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29761367/&quot;>https://pubmed.ncbi.nlm.nih.gov/29761367</a></p></li><li><p>Sheppard, JD, et al., &amp; Jasek, MC (2019). Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. <i>Ophthalmology and therapy</i> 8(2) 347–348. DOI:<a href=&quot;https://doi.org/10.1007/s40123-019-0172-z&quot;>10.1007/s40123-019-0172-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30783961/&quot;>https://pubmed.ncbi.nlm.nih.gov/30783961</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01BC10;
